DCC5089 |
Terutroban Sodium |
Selective Thromboxane_receptor>thromboxane receptor antagonist |
|
DCC5090 |
Tet3.0 |
Mutually Orthogonal Bioorthogonal Amino Acid, Enabling Efficient Protein Dual-Labeling in Cells |
|
DCC5091 |
Tetrabenazine |
Reversible inhibitor of vesicular monoamine transporter 2, showing anti-chorea effect and decreasing uptake of monamines into synaptic vesicles, as well as depletion of monoamine storage |
|
DCC5092 |
Tetrabromobisphenol A |
Activator of the hepatic interferon pathway in rats |
|
DCC5093 |
Tetracenomycin X |
Potent inhibitor of protein synthesis, inhibiting translation by binding within the ribosomal exit tunnel |
|
DCC5094 |
Tetrazanbigen |
Inducer of S phase arrest and apoptosis in hepatocellular carcinoma QGY-7701 |
|
DCC5095 |
Texaline |
Antitubercular agent |
|
DCC5096 |
Texasin |
Potent and selective human leukocyte 5-lipoxygenase (5-LOX) inhibitor |
|
DCC5097 |
Tezosentan |
Novel endothelin (ET) receptor antagonist |
|
DCC5098 |
Tfah-10n |
Novel multipotent anti-Alzheimer agent, selectively inhibiting human butyrylcholinesterase (BChE), having strong antioxidant activity and good β-amyloid (Aβ) anti-aggregation properties |
|
DCC5099 |
Tfgf-18 |
Novel GSK-3β inhibitor, showing anti-neuroinflammatory effects in lipopolysaccharide (LPS) activation of spontaneously immortalized SIM-A9 microglial cells and of mouse cortical microglia, inhibiting LPS-induced production of nitric oxide and the proinfla |
|
DCC5100 |
Tfmo-1 |
Novel cell-active, selective class IIa HDAC inhibitor |
|
DCC5101 |
Tfmo-12 |
CNS-penetrant selective class IIa histone deacetylase (HDAC) inhibitor, exploiting the >100-fold selectivity over class I/IIb HDACs |
|
DCC5102 |
Tfr4oht |
Cyclized tamoxifen analog, selective ER modulator (SERM) |
|
DCC5103 |
Tg-0054 |
Novel and Potent Stem Cell Mobilizer; Inhibitor of SDF-1α/CXCR4 binding |
|
DCC5104 |
Tg-0205221 |
Novel potent SARS coronavirus (CoV) 3CL protease inhibitor (Ki = 53 nM) |
|
DCC5105 |
Tg100948 |
Novel dual VEGFR/Src kinase inhibitor |
|
DCC5106 |
Tg101114 |
Novel inhibitor of T315I mutant enzyme, exhibiting reasonable in vivo efficacy in a xenograft mouse model harboring T315I |
|
DCC5107 |
Tg11-77 Hydrochloride |
Novel, Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist |
|
DCC5108 |
Tg-2112x |
Novel inhibitor of mitochondrial calcium uptake (#333333; font-family: "Open Sans", HelveticaNeue, "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 15px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: |
|
DCC5109 |
Tg2-in-3h |
Highly selective, potent, cell-permeable fluorescent irreversible tissue transglutaminase (TG2) inhibitor |
|
DCC5110 |
Tg3-95-1 |
EP2 allosteric potentiator |
|
DCC5111 |
Tg4-166 |
Potent and selective nociceptin opioid receptor (NOP) agonist |
|
DCC5112 |
tg4-290-1 |
Potent and selective nociceptin opioid receptor (NOP) agonist |
|
DCC5113 |
tg4-292-1 |
Potent and selective nociceptin opioid receptor (NOP) agonist |
|
DCC5114 |
Tg4-294-2 |
Potent and Selective Antagonist for Human EP2 Receptors |
|
DCC5115 |
Tgp-200c |
Novel potent and structure-specific inhibitor of pre-miR-200c, reversing a type 2 diabetes phenotype |
|
DCC5116 |
Tgr5 Agonist 11d-na |
Novel potent TGR5 agonist, displayind a significant glucose-lowering effect and stimulated GLP-1 and insulin secretion in TGR5H88Y mice but not in wild-type animals |
|
DCC5117 |
Tgr5-agonist-17 |
Novel Potent Agonist of TGR5 Receptor |
|
DCC5118 |
Tgx-115 |
Cell-permeable, potent, and selective inhibitor of PI 3-K isoforms p110ß/p110d |
|